In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Integra Life Sciences/ArthroCare

This article was originally published in The Gray Sheet

Executive Summary

510(k) clearance for ArthroCare's Coblation-based spinal surgery system for use in neurosurgery allows Integra to launch the product immediately in the U.S. under an agreement for marketing in North and South America (1"The Gray Sheet" July 31, 2000, p. 18). ArthroCare received a CE mark for the product in February

You may also be interested in...



TriPath Investment By Roche Boosts Stock 36% In August, Index Jumps 11%

A $40 mil. investment in TriPath Imaging by pharmaceutical and diagnostics giant Roche was the driving force behind a 36.1% jump in TriPath's stock price in August. The issue gained 2-3/16 to close the month at 8-1/4.

TriPath Investment By Roche Boosts Stock 36% In August, Index Jumps 11%

A $40 mil. investment in TriPath Imaging by pharmaceutical and diagnostics giant Roche was the driving force behind a 36.1% jump in TriPath's stock price in August. The issue gained 2-3/16 to close the month at 8-1/4.

Integra Boosts Neurosurgery Business Through Arthrocare Distribution Deal

Integra Lifesciences' decision to market Arthrocare's Coblation surgical system for brain tumor removal procedures is a part of the firm's ongoing strategy to bolster its growing neurology business.

Related Content

UsernamePublicRestriction

Register

MT013784

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel